Companies/Sunshine Biopharma, Inc.

Company profile

Sunshine Biopharma, Inc.

NASDAQ: SBFM · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Pointe-Claire, QCCIK 0001402328Reports USD

#474 of 1,394 Healthcare companies by revenue47th-percentile growth

EA Score

50D

FH 56DQ 45GM 50SS 32

v0.1 · 65/100 weight · provisional

↑ 3-yr revenue growth, balance-sheet leverage · ↓ Piotroski F, growth stability

Methodology →

Revenue TTM

$35.5M

Rev growth YoY (TTM)

-2.0%

Net income (FY)

-$6.0M

Employees

Market cap

$1.1M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$36.3M$36.3M2025

Net income-$6.0M-$6.0M2025

Operating income-$6.2M-$6.2M2025

Total assets$30.1M$30.1M2025

Liabilities$7.0M$7.0M2025

Equity$23.0M$23.0M2025

Revenue trend

FY2018 – FY2025 · USD

$447.2k

FY18

$21.1k

FY19

$71.4k

FY20

$228.4k

FY21

$4.3M

FY22

$24.1M

FY23

$34.9M

FY24

$36.3M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Sunshine Biopharma, Inc. booked $36.3M in FY2025 revenue, growing 4.1% year over year — about the middle of the pack among Healthcare companies we track, at a -16.5% net margin.

Peers · Healthcare

Evofem Biosciences, Inc.42D Dental Patient Care America, Inc.72B PharmaCom BioVet, Inc.——Herborium Group, Inc.36D

Key facts

CEOSteve N. Slilaty

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersPointe-Claire, QC

ExchangeNASDAQ: SBFM

Employees52

IPO date2022-02-15

Latest filings

8-K2026-07-10 8-K2026-05-29 8-K2026-05-19 10-Q2026-05-13 8-K2026-04-09 10-K2026-04-03 8-K2026-03-09 8-K2026-02-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.